WELT CEO Kang Sung-ji on growing the digital therapeutics market together
Forbes Korea “Trend Leading Companies with Jinho Park”, Episode 7: an interview with Kang Sung-ji (강성지) of WELT (웰트) (2022.06). In a brand-new category, building trust and growing the pie together matters more than winning the "first" title.
An interview series with the entrepreneurs who will lead Korea over the next decade — 15 innovators beyond beauty, from agtech and AI to robotics, digital therapeutics and F&B. That is why BEAUS COMPANY aims to grow beyond beauty — expanding and thriving together with every Korean industry.
Source: Forbes Korea, 2022.06, 「박진호가 만난 TREND LEADING COMPANIES(7) 강성지 웰트 대표」 · © Forbes Korea · Read the original on Forbes Korea (Korean) ↗
This is BEAUS COMPANY’s own summary and commentary based on the original Forbes Korea article (in Korean). The original article is © Forbes Korea.

WELT began as an in-house venture at Samsung Electronics and was spun off in 2016. It started with a smart belt for managing abdominal obesity, then moved into a digital therapeutic for insomnia, Pillow Rx, which received approval for a confirmatory clinical trial from Korea's Ministry of Food and Drug Safety (MFDS) in September 2021. At the time of the interview, patient recruitment was complete, and the company had closed a Series B of over KRW 14 billion in early 2022.
CEO Kang Sung-ji describes digital therapeutics as software that is prescribed. AI analyzes everyday data such as step counts, sunlight exposure and sleep time to measure sleep, and the app can only be used with an authorization code issued after a doctor's prescription. He chose mental health because, in his "digital twin" view, part of a person's inner world is reflected in their smartphone.
When moderator Park Jin-ho asked about the race to become Korea's first approved digital therapeutic, Kang said that growing the pie together matters more than the "first" title. WELT is preparing a decentralized clinical trial collaboration with Pear, which won approval earlier in the US, and follows the message: think like a bio company, build like a medical device maker, and move like an IT company.
Beaus Company sees two takeaways. First, game-like engagement design that keeps users from dropping off becomes a core capability even in treatment. Second, recruitment messages aimed at the exact moment of need, such as people still awake past midnight, can lower the barrier to participation. The same principles apply to marketing any functional category that must prove its efficacy.
Read the full interview on Forbes Korea →
- WELT was spun off in 2016 as Samsung Electronics' 11th in-house spin-off and expanded from a smart belt into an insomnia digital therapeutic.
- Its insomnia digital therapeutic Pillow Rx received MFDS approval for a confirmatory clinical trial in September 2021, and patient recruitment was complete at the time of the interview.
- Kang Sung-ji argues that early and later entrants growing the pie together matters more than the race for the "first" title.
- WELT brought in investors from pharmaceuticals, games and insurance as partners, each offering know-how it needs.
- Kang sees decentralized clinical trials lowering the recruitment barrier, possibly gathering in a day the 100 patients that usually take a year.
“Rather than becoming competitors, it's important for digital therapeutics companies to grow the pie, some leading from the front and others following behind.”
From the interview — Kang Sung-ji, WELT · Forbes Korea
FAQ
What does WELT do?
WELT is a digital healthcare company that began as an in-house venture at Samsung Electronics and was spun off in 2016. It started with a smart belt that manages abdominal obesity and now focuses on developing Pillow Rx, a digital therapeutic for insomnia.
How does Pillow Rx work?
AI analyzes digital biomarkers collected in daily life, such as coffee purchase history, sunlight exposure, step counts and sleep time, to measure sleep data automatically. It can only be used after entering an authorization code issued once a doctor prescribes it.
What is the key message of the interview?
On the race to launch Korea's first digital therapeutic, Kang Sung-ji said growing the pie together as an industry matters more than the "first" title. WELT is preparing a decentralized clinical trial collaboration with Pear in the US and follows the motto "think like a bio company, build like a medical device company, and move like an IT company."
Read the full interview on Forbes Korea → About the moderator, Jinho Park
Source: Forbes Korea, 2022.06, 「박진호가 만난 TREND LEADING COMPANIES(7) 강성지 웰트 대표」 · © Forbes Korea · Read the original on Forbes Korea (Korean) ↗
This is BEAUS COMPANY’s own summary and commentary based on the original Forbes Korea article (in Korean). The original article is © Forbes Korea.